{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T06:40:49Z","timestamp":1772088049676,"version":"3.50.1"},"reference-count":25,"publisher":"BMJ","issue":"11","funder":[{"name":"Grants from the National Agency of Scientific and Technological Promotion from Argentina","award":["PICT-2015-1820"],"award-info":[{"award-number":["PICT-2015-1820"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:p>Trilateral retinoblastoma (TRb) presents a management challenge, since intracranial tumours are seldom times resectable and quickly disseminate. However, there are no risk factors to predict the final outcome in each patient.<\/jats:p><jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate minimal disseminated disease (MDD) in the bone marrow (BM) and the cerebrospinal fluid (CSF) at diagnosis and during follow-up and reviewing its potential impact in the outcome of patients with TRb.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and analysis<\/jats:title><jats:p>We evaluated MDD in five patients with TRb, detecting the mRNA of <jats:italic>CRX<\/jats:italic> and\/or <jats:italic>GD2<\/jats:italic>, in samples from BM and CSF, obtained at diagnosis, follow-up and relapse.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Treatment involved intensive systemic chemotherapy in four patients, one did not receive this treatment and died of progression of the disease. Two patients underwent stem cell rescue. Three patients had leptomeningeal relapse and died. One patient remains disease-free for 84 months. <jats:italic>RB1<\/jats:italic> mutations were identified in the five patients, all of them were null mutations. At diagnosis, one patient had tumour cells in the CSF, and none had the BM involved. Only one case of four presented MDD during follow-up in the CSF, without concomitant detection in the BM. On leptomeningeal relapse, no case had MDD in the BM. In all these cases, cells in the CSF were positive for <jats:italic>GD2<\/jats:italic> and\/or <jats:italic>CRX<\/jats:italic>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>CSF dissemination always concluded in the death of the patient, without concomitant systemic dissemination denoting the importance of increasing treatment directed to the CSF compartment. The MDD presence could indicate a forthcoming relapse.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bjophthalmol-2018-312263","type":"journal-article","created":{"date-parts":[[2018,8,27]],"date-time":"2018-08-27T16:18:57Z","timestamp":1535386737000},"page":"1597-1601","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Minimal disseminated disease evaluation and outcome in trilateral retinoblastoma"],"prefix":"10.1136","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6100-5492","authenticated-orcid":false,"given":"Ana V","family":"Torbidoni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Sampor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viviana E","family":"Laurent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosario","family":"Aschero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saipriya","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Alderete","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel F","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Szijan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo L","family":"Chantada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2018,8,27]]},"reference":[{"key":"2020050713002812000_102.11.1597.1","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2008.150292"},{"key":"2020050713002812000_102.11.1597.2","doi-asserted-by":"publisher","DOI":"10.1177\/0883073815587943"},{"key":"2020050713002812000_102.11.1597.3","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.cancergen.2013.11.001","article-title":"Two novel cases of trilateral retinoblastoma: genetics and review of the literature","volume":"206","author":"D'Elia","year":"2013","journal-title":"Cancer Genet"},{"key":"2020050713002812000_102.11.1597.4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70336-5"},{"key":"2020050713002812000_102.11.1597.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2015.09.009"},{"key":"2020050713002812000_102.11.1597.6","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1200\/JCO.2000.18.1.236","article-title":"Chemoreduction for retinoblastoma may prevent trilateral retinoblastoma","volume":"18","author":"Shields","year":"2000","journal-title":"J Clin Oncol"},{"key":"2020050713002812000_102.11.1597.7","doi-asserted-by":"publisher","DOI":"10.1080\/13816810802043678"},{"key":"2020050713002812000_102.11.1597.8","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22336"},{"key":"2020050713002812000_102.11.1597.9","doi-asserted-by":"publisher","DOI":"10.1080\/13816810902988780"},{"key":"2020050713002812000_102.11.1597.10","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2011.108"},{"key":"2020050713002812000_102.11.1597.11","doi-asserted-by":"crossref","first-page":"505","DOI":"10.2214\/ajr.183.2.1830505","article-title":"Trilateral retinoblastoma: clinical and radiologic progression","volume":"183","author":"Provenzale","year":"2004","journal-title":"AJR Am J Roentgenol"},{"key":"2020050713002812000_102.11.1597.12","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.69.10.749"},{"key":"2020050713002812000_102.11.1597.13","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2011.23"},{"key":"2020050713002812000_102.11.1597.14","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19910201)67:3<710::AID-CNCR2820670330>3.0.CO;2-3"},{"key":"2020050713002812000_102.11.1597.15","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0002-9394(14)77408-2","article-title":"Successful therapy for trilateral retinoblastoma","volume":"114","author":"Nelson","year":"1992","journal-title":"Am J Ophthalmol"},{"key":"2020050713002812000_102.11.1597.16","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1001\/jamaophthalmol.2015.0900","article-title":"Association of Cone-Rod Homeobox transcription factor messenger RNA with pediatric metastatic retinoblastoma","volume":"133","author":"Torbidoni","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"2020050713002812000_102.11.1597.17","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-1004(200001)15:1<7::AID-HUMU4>3.0.CO;2-N"},{"key":"2020050713002812000_102.11.1597.18","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200606000-00009"},{"key":"2020050713002812000_102.11.1597.19","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1016\/j.ejca.2013.04.021","article-title":"Detection of minimally disseminated disease in the cerebrospinal fluid of children with high-risk retinoblastoma by reverse transcriptase-polymerase chain reaction for GD2 synthase mRNA","volume":"49","author":"Laurent","year":"2013","journal-title":"Eur J Cancer"},{"key":"2020050713002812000_102.11.1597.20","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1002\/pbc.25631","article-title":"A phase I study of the anti-idiotype vaccine racotumomab in neuroblastoma and other pediatric refractory malignancies","volume":"62","author":"Cacciavillano","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"2020050713002812000_102.11.1597.21","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1001\/jamaophthalmol.2016.4158","article-title":"Minimal disseminated disease in nonmetastatic retinoblastoma with high-risk pathologic features and association with disease-free survival","volume":"134","author":"Laurent","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"2020050713002812000_102.11.1597.22","doi-asserted-by":"crossref","unstructured":"Garzia L , Kijima N , Morrissy AS , et al . A hematogenous route for medulloblastoma leptomeningeal metastases. Cell 2018;173:1549.doi:10.1016\/j.cell.2018.05.033","DOI":"10.1016\/j.cell.2018.05.033"},{"key":"2020050713002812000_102.11.1597.23","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0002-9394(89)90209-2","article-title":"Seven cases of trilateral retinoblastoma","volume":"107","author":"Pesin","year":"1989","journal-title":"Am J Ophthalmol"},{"key":"2020050713002812000_102.11.1597.24","doi-asserted-by":"crossref","first-page":"e294","DOI":"10.1111\/aos.12578","article-title":"Immunoreactivity of the 14F7 Mab raised against N-Glycolyl GM3 Ganglioside in retinoblastoma tumours","volume":"93","author":"Torbidoni","year":"2015","journal-title":"Acta Ophthalmol"},{"key":"2020050713002812000_102.11.1597.25","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1097\/WCO.0000000000000491","article-title":"The promises of immunotherapy in gliomas","volume":"30","author":"Mildenberger","year":"2017","journal-title":"Curr Opin Neurol"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjophthalmol-2018-312263","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T08:57:52Z","timestamp":1601110672000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjophthalmol-2018-312263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,27]]},"references-count":25,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2018,10,22]]},"published-print":{"date-parts":[[2018,11]]}},"alternative-id":["10.1136\/bjophthalmol-2018-312263"],"URL":"https:\/\/doi.org\/10.1136\/bjophthalmol-2018-312263","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"value":"0007-1161","type":"print"},{"value":"1468-2079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,27]]}}}